Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies.

ABSTRACT:

Background

Smoking is a major risk factor for COPD and may impact the efficacy of COPD treatments; however, a large proportion of COPD patients continue to smoke following diagnosis.

Methods

This post-hoc analysis of pooled data from the replicate 12-week, placebo-controlled GEM1 and GEM2 studies assessed the impact of smoking status on the efficacy and safety of glycopyrrolate 15.6 μg twice daily vs placebo in patients with moderate-to-severe COPD. Data from 867 patients enrolled in GEM1 and GEM2 were pooled for analysis and grouped by smoking status (57% current smokers, 43% ex-smokers). Forced expiratory volume in 1 s (FEV₁) area under the curve from 0 to 12 h, trough FEV₁, forced vital capacity, St George's Respiratory Questionnaire (SGRQ) total sco

SUBMITTER: Tashkin DP 

PROVIDER: S-EPMC6604131 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature